Treatment of cannabis-based drug for glioblastoma

In a new three-year phase II trial of ARISTOCRAT, the scientists from the University of Leeds have started using Sativex along with chemotherapy for recurrent glioblastoma. Currently, the average survival rate for patients with this diagnosis is less than 10 months. 230 participants will be involved in the study.

Sativex (nabiximols) is an oral spray that contains two types of chemically active compounds of cannabis, THC (tetrahydrocannabinol) and CBD (cannabidiol). The first is used in medicine as a relaxant and anesthetic, the third is a psychoactive compound. It is the only marijuana-based drug in the world that contains tetrahydrocannabiol in addition to cannabidiol. This drug has been developed by the British company GW Pharma, which specializes in the treatment of neurological diseases.

Source: clinicaltrialsarena